The Acton, Massachusetts–based company said the updates to its tubeless, wearable automated insulin delivery patch pump’s algorithm include a new benchmark in tubeless diabetes technology with a lower, 100 mg/dL target glucose option. It also delivers a more seamless automated experience.
Omnipod 5 is the first FDA-cleared tubeless automated insulin delivery system available on the market. It communicates with a CGM to proactively correct for glucose highs every five minutes and protect against lows with insulin dosing.
Insulet plans to continue enhancing the system and looking toward next-generation technologies. CEO Ashley McEvoy outlined some of the planned improvements in a recent interview with Drug Delivery Business News, while she and other Insulet leaders expanded on those plans during the company’s recent Investor Day event.
Get the full story at our sister site, Drug Delivery Business News.
